Somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Equine metabolic syndrome (EMS) is an endocrinopathy affecting horses and ponies. It is of primary concern due to its link to obesity, insulin dysregulation, and subsequent laminitis. There are some similarities in clinical signs between EMS and pituitary pars intermedia dysfunction, also known as PPID or Cushing's disease, and some equines may develop both, but they are not the same condition, having different causes and different treatment.
Both doxycycline (DOX) and folic acid were incorporated onto the surface of protein covalently. The very low toxicity of polymer-protein nanoconjugates effectively avoided the high toxicity of DOX, which is expected to not only reduce toxic side effects, but also improve anticancer efficiency in vitro examinations.
==== Oxidation of biomass ==== Formic acid can also be obtained by aqueous catalytic partial oxidation of wet biomass by the OxFA process. A Keggin-type polyoxometalate (H5PV2Mo10O40) is used as the homogeneous catalyst to convert sugars, wood, waste paper, or cyanobacteria to formic acid and CO2 as the sole byproduct. Yields of up to 53% formic acid can be achieved.
=== Central bankers === In a joint public statement released the day after Powell announced the subpoenas and investigation, former Federal Reserve Chairs Alan Greenspan, Ben Bernanke, and Janet Yellen, former U.S. Secretaries of the Treasury Henry Paulson, Timothy Geithner, Robert Rubin, and Jacob Lew, economists Glenn Hubbard, Kenneth Rogoff, and Jared Bernstein with others in defense of Powell that argued that the investigation was "an unprecedented attempt to use prosecutorial attacks to undermine [the Federal Reserve's] independence", and that "This is how monetary policy is made in emerging markets with weak institutions, with highly negative consequences for inflation and the functioning of their economies more broadly". In an interview with CNBC, Yellen further condemned the investigation and stated that Trump's demands for the Federal Reserve to cut its interest rates to lower interest payments on the national debt "is the road to a banana republic." Likewise, New York Federal Reserve Bank President John C. Williams, Chicago Federal Reserve Bank President Austan Goolsbee, Minneapolis Federal Reserve Bank President Neel Kashkari, and Atlanta Federal Reserve Bank President Raphael Bostic publicly criticized the investigation as undermining the Federal Reserve's independence while speaking in defense of Powell's personal character, echoing concerns about potentially higher inflation, and asserting that the investigation is about the central bank's monetary policies rather than the cost overruns of the renovation projects.
=== Porosity Measurements and Surface Analysis === Gas sorption analysis provides crucial information about the porosity and surface properties of organic molecular cages. Nitrogen adsorption-desorption isotherms determine surface area, pore volume, and pore size distribution. BET surface area measurements typically reveal values ranging from 500 to 3000 m²/g, depending on cage structure. The analysis of adsorption isotherms also provides insights into pore accessibility and connectivity. Carbon dioxide and hydrogen adsorption measurements evaluate potential applications in gas storage and separation.
Sources: en.wikipedia.org
== Veterinary uses == In February 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Omeprazole TriviumVet, gastro-resistant capsule, hard, intended for dogs. The applicant for this veterinary medicinal product is TriviumVet DAC. Omeprazole TriviumVet was authorized for veterinary use in the European Union in April 2025.
10 December – Foreign Secretary David Cameron threatens to withdraw co-operation with Scottish ministers following a meeting between Humza Yousaf, the First Minister of Scotland, and Turkish President Recep Tayyip Erdogan at the 2023 United Nations Climate Change Conference, which took place without the presence of a UK official and was consequently a breach of protocol. In response, Yousaf calls the threat "petty" and "misguided". 11 December – New modernised trains are introduced on the Glasgow Subway as part of a £288m upgrade of the city's underground rail system. The Foreign and Commonwealth Office is to move from its Abercrombie House offices in East Kilbride to an undisclosed location in Glasgow some time after 2025, it is announced, with His Majesty's Revenue and Customs moving from Queensway House to replace the FCO at Abercrombie House. 12 December – Five men are charged in connection with historic sexual abuse at Edinburgh Academy. Perth and Kinross Council provisionally approves a 100% increase in Council Tax on second homes. 13 December – Nuns Sister Sarah McDermott, 79, and Sister Eileen Igoe, 79, and carer Margaret Hughes, 76, are convicted of mistreating children at Smyllum Park, an orphanage in Lanark, from 1969 until its closure in 1981. 14 December – Robert O'Brien, aged 45, Andrew Kelly, 44, and Donna Marie Brand, also aged 44, are convicted of the 1996 murder of Caroline Glachan following a trial at the High Court in Glasgow. All three were teenagers at the time the crime was committed.
== Structure == The LRP1 gene encodes a 600 kDa precursor protein that is processed by furin in the trans-Golgi complex, resulting in a 515 kDa alpha-chain and an 85 kDa beta-chain associated noncovalently. As a member of the LDLR family, LRP1 contains cysteine-rich complement-type repeats, EGF (gene) repeats, β-propeller domains, a transmembrane domain, and a cytoplasmic domain. The extracellular domain of LRP1 is the alpha-chain, which comprises four ligand-binding domains (numbered I-IV) containing two, eight, ten, and eleven cysteine-rich complement-type repeats, respectively. These repeats bind extracellular matrix proteins, growth factors, proteases, protease inhibitor complexes, and other proteins involved in lipoprotein metabolism. Of the four domains, II and IV bind the majority of the protein's ligands. The EGF repeats and β-propeller domains serve to release ligands in low pH conditions, such as inside endosomes, with the β-propeller postulated to displace the ligand at the ligand binding repeats. The transmembrane domain is the β-chain, which contains a 100-residue cytoplasmic tail. This tail contains two NPxY motifs that are responsible for the protein's function in endocytosis and signal transduction.
9 November – Buckingham Palace announces that Queen Camilla will miss Remembrance events held over the weekend as she recovers from a chest infection. 10 November – First Minister of Northern Ireland Michelle O'Neill becomes the first senior Sinn Féin figure to take part in an official Remembrance Sunday ceremony, held in Belfast. 11 November The Terminally Ill Adults (End of Life) Bill, which would allow terminally ill people in England and Wales with less than six months to live to seek assistance in ending their lives, with the consent of two doctors and a High Court judge, is published. Helen-Ann Hartley, the Bishop of Newcastle, calls for Justin Welby to resign as the Archbishop of Canterbury following a damning report into prolific child abuser John Smyth QC, who was associated with the Church of England. At the Old Bailey, former soldier Daniel Khalife changes his plea midway through his trial, and pleads guilty to escaping from prison in September 2023. His trial on three other charges continues. At the invitation of French President Emmanuel Macron, Starmer travels to France to mark Armistice Day at the Tomb of the Unknown Soldier, then holds talks with Macron to affirm the UK and France's commitment to supporting Ukraine. 12 November The BBC confirms that Gary Lineker will step down as Match of the Day presenter at the end of the current season, but will host BBC Sport's coverage of the 2026 World Cup.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.